When Psoriasis Creams Stop Working

Why isn't the cream working?

Before anything stronger gets prescribed, most dermatologists check whether the topical was ever really delivered: how much came out of the tube, how often, over how many weeks, and whether the strength suited the plaque. A tube that lasted three months on thick knee plaques did not fail. It was a treatment that never quite happened, and it is the cheapest thing on this list to fix.

The AAD-NPF topical guideline pairs corticosteroids, used on plaques away from the skin folds, with agents that let the steroid do less of the work — a vitamin D analog, the retinoid tazarotene, or a topical calcineurin inhibitor 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids are recommended for psoriasis plaques outside the intertriginous areas, and that steroid-sparing agents — vitamin D analogs, tazarotene, and topical calcineurin inhibitors — sit alongside them and carry the load at facial and fold sites.. Plans written that way have two moving parts, and people often keep using one while quietly dropping the other. The vitamin-d analogs for psoriasis are usually the part abandoned first, because they work slowly and undramatically next to a potent steroid.

Three other things blunt a topical without anyone having done anything wrong:

• Vehicle mismatch. An ointment holds moisture against a thick plaque; a lotion on the same plaque mostly evaporates. On hair-bearing skin the reverse holds, and a greasy ointment never reaches the surface it was meant for.
• Surface area. Applying anything twice a day across a large area is a second job, and adherence falls the way any unpaid job's does.
• Untouched scale. A heavily scaled plaque is a barrier in its own right, and medication laid on top of it may never reach the skin underneath.

Establish that the topical was applied at the right strength, in the right vehicle, for the full period intended, before treating it as a failure.

Is it definitely psoriasis?

A plaque that refuses a properly run course of treatment is a reason to re-open the diagnosis, not only to escalate it. Several rashes look like psoriasis in ordinary light, behave differently under treatment, and can be made worse by exactly the drug prescribed for psoriasis. Re-examining at this point is routine, not evidence that someone got it wrong the first time.

Dermatophyte infection is the classic impostor on the trunk and legs. The CDC's clinical overview rests the diagnosis on a KOH preparation or a fungal culture rather than on appearance, and notes the emergence of antifungal-resistant Trichophyton species that need specialist management 2Ref 2Centers for Disease Control and Prevention (2024).Clinical Overview of Ringworm.That dermatophyte infection is diagnosed by KOH preparation or fungal culture rather than by appearance alone, and that antifungal-resistant Trichophyton species have emerged that require specialist management.. Confirming matters because the two conditions want opposite treatments, and the separate question of when antifungal cream fails has its own escalation path.

Seborrheic dermatitis is the impostor on the scalp, the eyebrows, the folds beside the nose, and the mid-chest. It is a clinical diagnosis made largely from where the rash sits — the sebum-rich areas — and it answers to antifungal or keratolytic shampoos, low-potency corticosteroids, and calcineurin inhibitors 3Ref 3Clark GW, Pope SM, Jaboori KA (2015).Diagnosis and Treatment of Seborrheic Dermatitis.That seborrheic dermatitis is a clinical diagnosis based on involvement of sebaceous-rich areas, and that it is treated with topical antifungals, low-potency corticosteroids, calcineurin inhibitors, and medicated shampoos on the scalp.. On a scalp the two are genuinely hard to separate by eye, and both can be present at once.

A scraping takes a minute in the room. A small punch biopsy takes a little longer and settles most of what is left. Neither is a large procedure, and either can save months.

Where the plaque sits changes the cream, not the diagnosis

Skin is not uniform, and the guideline treats certain sites on their own terms. Corticosteroids are recommended for plaques outside the intertriginous areas — the skin folds — while steroid-sparing options such as topical calcineurin inhibitors carry more of the load in the armpits, the groin, under the breasts, and on the face, where a potent steroid thins skin quickly 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids are recommended for psoriasis plaques outside the intertriginous areas, and that steroid-sparing agents — vitamin D analogs, tazarotene, and topical calcineurin inhibitors — sit alongside them and carry the load at facial and fold sites.. A cream failing there may be the wrong cream rather than the wrong tier.

The scalp. Hair is a delivery problem, not a disease problem. A foam, a solution, or a medicated shampoo reaches skin that an ointment cannot, which is why scalp psoriasis treatment is generally written as its own prescription rather than as a smaller copy of the body plan.

Nails. Topicals reach the nail plate easily and the matrix beneath it barely at all. Nail disease often pushes the conversation toward systemic treatment even when very little skin is involved, because there is no good topical answer to it.

Palms and soles. The skin there is thick, the site is in constant use, and a plaque that would be cosmetic on a back can stop someone working.

How severity gets counted, and why it decides what you can get

Access to everything above the topical tier runs through a number. Clinicians record how much of the body surface is involved and which sites are affected, and that record is what an insurer reads when deciding whether a systemic drug is covered. A documented account of failed topicals, with photographs and dates, moves a treatment plan further than another month of ointment does.

Two measures do most of the work. Body surface area is the clinic shorthand, estimated in palm-sized units across each region. PASI — the Psoriasis Area and Severity Index — is the research scale, combining redness, thickness, and scale with how much of each body region is involved. Neither captures a plaque on the genitals or a hand that splits open at the knuckles, which is why any discussion of psoriasis severity should cover where the disease is and not only how much of it there is.

Coverage rules differ by plan. Many ask for documentation that topical therapy was tried and did not control the disease before a systemic drug is approved, which quietly makes the clinic note part of the treatment. It is reasonable to ask at the visit exactly what the plan needs to see.

What is the next step above creams?

Above topical therapy sit three tiers, each with its own AAD-NPF guideline: phototherapy, drugs taken by mouth, and injected biologics. Which one comes next is not decided by seniority. Extensive disease can begin on a systemic drug, and someone whose whole problem is two immovable plaques may do better with targeted light than with any pill. The full psoriasis treatment ladder is set out separately.

Phototherapy is ultraviolet light given deliberately, in measured amounts. The guideline covers narrowband UVB, broadband UVB, PUVA, and the excimer laser, and separates them by whom each suits, what each cannot be combined with, and what each costs in adverse effects 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That the phototherapy tier comprises narrowband UVB, broadband UVB, PUVA, and the excimer laser, each with its own indications, contraindications, and adverse effects.. The excimer laser is aimed at individual plaques, which fits the person with limited but stubborn disease. The obstacle is usually the calendar: a course means repeated trips to a unit that has the equipment.

Oral drugs occupy the middle of the range. They deliver systemic treatment without an injection and are followed with periodic blood tests; apremilast for psoriasis is one of the newer options in this tier.

Biologics are injected antibodies aimed at a single inflammatory signal. The AAD-NPF sorts them by target — TNF, IL-17, IL-23, and the older IL-12/23 pathway — and sets out the screening required before a first injection and the monitoring expected afterwards 5Ref 5American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologics for psoriasis are grouped by molecular target (TNF, IL-17, IL-23, IL-12/23) and that each group carries defined pre-treatment screening and on-treatment safety monitoring..

If your joints hurt, say so before anything is prescribed

Joint symptoms change which drug is chosen, not merely how urgently. For active psoriatic arthritis, the American College of Rheumatology and the National Psoriasis Foundation conditionally place a TNF-inhibitor biologic ahead of the oral small-molecule drugs as first-line treatment 6Ref 6Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.That the ACR/NPF guideline conditionally recommends TNF-inhibitor biologics over oral small-molecule drugs as first-line therapy for active psoriatic arthritis, and that it also covers IL-12/23 and IL-17 inhibitors, abatacept, and tofacitinib.. A plan built entirely around skin can leave that side untreated, so the skin question and the joint question are best answered in the same conversation.

That guideline also covers the IL-12/23 and IL-17 inhibitors, abatacept, and tofacitinib 6Ref 6Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.That the ACR/NPF guideline conditionally recommends TNF-inhibitor biologics over oral small-molecule drugs as first-line therapy for active psoriatic arthritis, and that it also covers IL-12/23 and IL-17 inhibitors, abatacept, and tofacitinib., which is the practical point: several drugs act on the plaques and the joints together, and choosing one of those at the outset is simpler than adding a second drug a year later.

Describe joint symptoms plainly — which joints, when they are worst, whether anything is visibly swollen, and whether a whole finger or toe has puffed up rather than one knuckle. Say it even if nobody asks, and even if it seems unrelated to skin. Joint involvement can reorder the treatment ladder before the first prescription is written.

Making the next appointment count

The most useful thing to bring is a record. Photographs of the plaques at their worst, the name of every topical tried, roughly how long each ran, and what happened in the weeks after stopping will turn a short appointment into a decision. Without that record, a visit often ends with a prescription for something already tried and abandoned.

Worth having ready:

• The products themselves, or their names. Strength matters, and most people remember the color of the tube rather than what was in it.
• Where the disease actually is. Scalp, nails, ears, genitals, and skin folds get left off the list because they were not what the visit was about.
• What the disease costs. Sleep lost, clothes changed, work missed, swimming avoided. No severity scale measures any of it, and clinicians weigh it anyway.
• The plan's name, and whether prior authorization has already been mentioned. The answer shapes the sequence more than most people expect.

Running out of road with creams is an ordinary point in a long condition, not a sign the disease has become untreatable. It is the point at which the more effective options open up.